Potential for combined therapy with 348u87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir‐resistant herpes simplex virus infection

S. Safrin, Timothy W Schacker, J. Delehanty, E. Hill, L. Corey

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Inhibitors of the ribonucleotide reductase of herpes simplex viruses (HSV) potentiate the activity of acyclovir in vitro and in animal studies. In addition, the combination of the ribonucleotide reductase inhibitor 348U87 and acyclovir has synergistic therapeutic effects against infections in mice due to thymidine kinase‐deficient, thymidine kinase‐altered, and DNA polymerase mutants of HSV. We performed a pilot study of topical combination therapy with 348U87 (3%) and acyclovir (5%) cream for acyclovir‐resistant, anogenital HSV infections in ten human immunodeficiency virus (HIV)‐infected patients. Our results, with lack of complete reepitheliazation of lesions in all patients and poor virologic response, suggest that this therapy is unlikely to be useful for this indication.

Original languageEnglish (US)
Pages (from-to)146-149
Number of pages4
JournalJournal of Medical Virology
Volume41
Issue number1 S
DOIs
StatePublished - 1993

Keywords

  • HIV infection
  • HSV infection
  • topical 348U87

Fingerprint Dive into the research topics of 'Potential for combined therapy with 348u87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir‐resistant herpes simplex virus infection'. Together they form a unique fingerprint.

Cite this